It's a remedy that dates back to Pharaohs—one that doctors still use today to treat certain acute and chronic wounds, although in a different form than ancient Egyptian physicians knew.

Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today successful results of a Phase 1/2a clinical trial for treating ...

It's a remedy that dates back to Pharaohs-one that doctors still use today to treat certain acute and chronic wounds, ...

The global wound evacuators market is on a steady growth trajectory, with its size estimated at USD 383.3 million in 2022, and projected to reach USD 593.6 million by 2032, expanding at a CAGR of 4.1% ...

After three years of development, a smart insole designed by researchers at the University of Malta is showing promising ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 ...

The Asia-Pacific advanced wound dressings market is poised for robust growth, driven by the increasing prevalence of chronic wounds, advancements in wound care technology, and a growing elderly ...

The average plasma fibrinogen level was 681 ± 160 mg/dL, exceeding the normal range. Fibrinogen levels increased with ulcer severity, measuring 503.51 mg/dL for Wagner Grade 2, 623.45 mg/dL for Grade ...

Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices ...

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...